Oxford University spin-out Infinitopes Precision Immunomics has completed a £12.8 ($16) million seed funding round led by Octopus Ventures. The round was heavily oversubscribed, also drawing in funds from Cancer Research Horizons, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory,… Read More
Glen Clova Scientific has closed a £4 million (approximately $5 million) seed financing round, led by Norcliffe Capital together with investment from DSW Ventures, TRICAPITAL Angels and Scottish Enterprise. Glen Clova Scientific was founded in 2022 as a spin out from the University of Dundee to… Read More
This is the latest episode of the free DDW narrated podcast, titled “A look behind the scenes of the drug discovery industry” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Going paperless – the move to electronic lab… Read More
Xaira Therapeutics, a joint incubation by ARCH Venture Partners and Foresite Labs, has launched with more than $1 billion of committed capital from lead investors. Xaira is building a platform for drug discovery and development that it hopes will advance multiple drug programmes and unlock biological… Read More
The Birmingham Drug Discovery Hub (BDDH) has been set up to help University of Birmingham researchers to overcome the ‘valley of death’, where projects fail due to the funding gap between original research and commercial investment. The hub has attracted more than £4 ($4.9) million in… Read More
Bios Health Group has launched the Bios Innovation Circle – a new venture studio and strategic hub, designed to support biotechnology and life science companies towards growing success. The Bios Innovation Circle is a venture studio and strategic hub designed to catalyse the growth of start-ups,… Read More
Neurosterix has launched with a $63 million Series A financing led by Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures. The company will acquire Addex’s allosteric modulator discovery technology platform. The platform has a track record of identifying highly… Read More
A project focused on developing a small RNA-based platform technology for treating monogenic diseases, smartRNA, has joined the BioInnovation Institute’s (BII) Bio Studio programme. The approach to achieve this involves delivering an engineered small artificial (smart)RNA into the cell, where it assembles with endogenous protein co-factors… Read More
DDW Editor Reece Armstrong speaks to Michael Krogh Jensen, Co-founder and CEO of Biomia, about developing plant-based medicines and what recent investment and support from the Bio Studio programme means for its pipeline. RA: How has being part of the Bio Studio programme helped you develop your pipeline?… Read More
A UK-based start-up is developing technology to build a pharmaceuticals factory in space that will make antibody treatments more accessible and easier to administer. BioOrbit is aiming to build the first pharmaceuticals factory in microgravity and are currently developing a platform for large-scale crystallisation of protein… Read More
This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: European drug discovery and development success stories,… Read More
Cancer Research Horizon’s Innovation Summit 2023 took place on 21 November 2023 at the Royal Society of Medicine, and included talks from researchers translating their research, as well as networking with members of the entrepreneurial ecosystem. DDW’s Megan Thomas spoke to a range of attendees. Trends… Read More
Obulytix, a spin-off based on research results from Ghent University and KU Leuven, has built a platform that creates new ways to tackle bacterial infections. The phage lysin-based platform – using artificial intelligence (AI) – has attracted a significant €4 million investment from Boehringer Ingelheim Venture… Read More
The first set of speakers for Rejuvenation Startup Summit 2024 (Berlin, 10-11 May 2024) has been announced. The networking event aims to bring together startups and members of the longevity venture capital/investor ecosystem to create therapies to vastly extend the healthy human lifespan. In… Read More
Listen to this article on the DDW Podcast: DenovAI is the second start-up to launch from the global pharma consortium AION Labs – an organisation that aims to improve the drug discovery and development process through the use of AI and other computational technologies. DDW Editor… Read More
This is the latest episode of the free DDW narrated podcast, “Drug discovery success stories”, which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Global pharma start-up success stories”, and “Excitement at rectal… Read More
